Sanofi top pharmaceutical products 2017-2021
Lantus was Sanofi’s second best-selling pharmaceutical product in 2020 according to the company’s latest annual financial report. The long-acting insulin (glargine), used to treat diabetes type I and II, generated some 2.5 billion U.S. dollars worldwide. Lantus has been among the company’s top products for many years but has shown significant decrease in revenue since the patent expired during 2015. In 2016, Sanofi introduced a much more potent formulation of insulin glargine under the brand name Toujeo.
Diabetes treatment
Diabetes is one of the most prevalent chronic diseases worldwide. Accordingly, antidiabetics form one of the three largest therapy classes within the global pharmaceutical market. Diabetes means that the human body is not able to produce its own insulin or use its insulin effectively. While persons with type 1 diabetes always need insulin for treatment, diabetes type 2 patients do not necessarily need it. A key medicine for persons with type 2 diabetes is metformin which helps to control blood sugar and to use insulin effectively. Change in lifestyle, a balanced diet, and physical activity might also be important parts of diabetes treatment.
The diabetes market
As mentioned, the diabetes segment is one of the largest single therapy classes within the pharmaceutical market, projected to generate nearly 150 billion U.S. dollars in 2025 worldwide. With projected increasing numbers of people affected worldwide until 2045, the diabetes market is also expected to grow. Currently, French company Sanofi is the world’s second largest antidiabetics manufacturing company based on revenue, only topped by Danish company Novo Nordisk. It is expected that Novo Nordisk will extend its market share in the diabetes sector up to 35 percent until 2024, thus maintaining the global leading position.
Diabetes treatment
Diabetes is one of the most prevalent chronic diseases worldwide. Accordingly, antidiabetics form one of the three largest therapy classes within the global pharmaceutical market. Diabetes means that the human body is not able to produce its own insulin or use its insulin effectively. While persons with type 1 diabetes always need insulin for treatment, diabetes type 2 patients do not necessarily need it. A key medicine for persons with type 2 diabetes is metformin which helps to control blood sugar and to use insulin effectively. Change in lifestyle, a balanced diet, and physical activity might also be important parts of diabetes treatment.
The diabetes market
As mentioned, the diabetes segment is one of the largest single therapy classes within the pharmaceutical market, projected to generate nearly 150 billion U.S. dollars in 2025 worldwide. With projected increasing numbers of people affected worldwide until 2045, the diabetes market is also expected to grow. Currently, French company Sanofi is the world’s second largest antidiabetics manufacturing company based on revenue, only topped by Danish company Novo Nordisk. It is expected that Novo Nordisk will extend its market share in the diabetes sector up to 35 percent until 2024, thus maintaining the global leading position.
